Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CA 103

X
Drug Profile

CA 103

Alternative Names: CA-103

Latest Information Update: 28 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Curigin
  • Class Antineoplastics; Small interfering RNA
  • Mechanism of Action Androgen receptor antagonists; MTOR protein inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Benign prostatic hyperplasia; Prostate cancer

Most Recent Events

  • 23 Jun 2023 Early research in Benign prostatic hyperplasia in South Korea (IV) (Curigin pipeline, June 2023)
  • 23 Jun 2023 Early research in Prostate cancer in South Korea (IV) (Curigin pipeline, June 2023)
  • 04 Aug 2022 Curigin has patent protection for CA 103 entitled "Nucleic acid simultaneously inhibiting expression of AR gene and mTOR gene" in Australia, Japan and the US
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top